Compare ProShares Ultra Bitcoin ETF (BITU) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Bitcoin ETF vs GSK plc — how do they compare? ProShares Ultra Bitcoin ETF trades at $9.77, while GSK plc trades at $51.35 (market cap $101.55B). The key difference: GSK plc pays a 3.5% dividend while ProShares Ultra Bitcoin ETF pays none, and GSK plc is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITU | GSK | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $64.41 | $61.18 |
52-Week Low | $8.12 | $36.20 |
Market Cap | — | $101.55B |
Enterprise Value | — | $122.16B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITU trades at $9.01, down 5.16% over 24 hours amid bearish technical signals. The stock shows weak momentum with moving averages indicating a downtrend and oscillators neutral. Recent news highlights concerns over its leveraged ETF structure causing underperformance versus Bitcoin. The company pays small dividends but key valuation and profitability ratios are unavailable.
Outlook remains cautious due to structural decay risks and negative sentiment. Investment opportunity is limited to speculative traders during sustained bull markets, but risks of volatility decay and investor selling pressure outweigh potential gains in the near term.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Bitcoin ETF
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
